Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Carcinoma, Non-Small-Cell Lung 8Glioblastoma 7Carcinoma, Renal Cell 7Lung Neoplasms 6Colorectal Neoplasms 6Brenner Tumor 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Spinal Cord Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Colonic Neoplasms 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

tocilizumab 1ceftolozane, tazobactam drug combination 1Ribavirin 1Nebulizers and Vaporizers 1Methylprednisolone 1Lidocaine 1Immunoglobulin G 1Gelsolin 1Etanercept 1Disulfides 1Calcitriol 1Blood Specimen Collection 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pneumonia × Immunoglobulin G × Clear all
NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

National Cancer Institute (NCI)

Phase 2 Terminated
1 enrolled 10 charts
Other hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡